•      135 patients, out of a total planned 182, have been randomized and were administered the first injection of AllocetraTM; enrollment actively ongoing at clinical sites in the United States and in Europe
•      Topline six-month data expected by mid-2027
•      Phase 2b builds on positive three- and six-month Phase 1/2a data, which supported FDA Regenerative Medicine Advanced Therapy (RMAT) designation granted in July 2026

Nes-Ziona, Israel, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced that 135 patients, out of a total planned 182, have been randomized and were administered the first injection of AllocetraTM in the Company’s Phase 2b clinical trial of Allocetra™ for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA). The trial is actively recruiting at clinical sites in the United States, Denmark and Poland, and the Company expects to report topline six-month data by mid-2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.